Krystal Biotech (KRYS) Corporate presentation summary

Financial performance and growth

• Achieved 12 consecutive quarters of positive EPS, with 2Q 2026 EPS at $1.79.

• Over $965M in global net revenue from VYJUVEK since launch.

• Cash and investments totaled $1.1B as of 2Q 2026.

• Expanding footprint in the U.S., Europe, and Japan, supported by 175K+ sq ft cGMP manufacturing capacity.

Product portfolio and pipeline

• VYJUVEK is the first corrective therapy for dystrophic epidermolysis bullosa (DEB), approved in the U.S., Europe, and Japan.

• Four rare disease registrational study readouts expected in the next two years, including KB803 (corneal abrasions in DEB), KB801 (neurotrophic keratitis), KB407 (cystic fibrosis), and KB111 (Hailey-Hailey disease).

• Deep pipeline includes programs in oncology, aesthetics, and additional lung and skin indications.

VYJUVEK clinical and commercial highlights

• Demonstrated significant efficacy and safety in pivotal studies, with up to 68% wound healing at 6 months in DEB patients.

• Well tolerated with mostly mild or moderate adverse events; no treatment discontinuations or deaths.

• Strong U.S. launch with broad reimbursement, label expansion, and over 730 patients approved for coverage.

• Global expansion underway, with launches in France, Germany, and Japan in 2H 2025.